2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2389

MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis
Abstract Number: 932

MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2679

Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus
Abstract Number: 2974

Multi-Biomarker Disease Activity Score Is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State
Abstract Number: 2189

Multicentric Reticulohistiocytosis- Case Series from a Tertiary Care Center
Abstract Number: 2244

Multimedia Patient Education Tool for Patients with Osteoarthritis
Abstract Number: 2005

Multimedia Patient Education Tool for Patients with Osteoporosis
Abstract Number: 427

Multimedia Patient Education Tool for Patients with Rheumatoid Arthritis
Abstract Number: 2475

Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study
Abstract Number: 2006

Multiple Joint Osteoarthritis: Patient Preferences for a Generic Exercise and Self-Management Programme
Abstract Number: 950

Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis
Abstract Number: 1137

Multiway Transcriptomic Analysis of Monocyte-Derived Dendritic Cells Discriminates Effects of Disease and of HLA-B27 in Spondyloarthritis
Abstract Number: 721

Muscle Disease in Systemic Sclerosis Is Associated with an Increased Risk for Cardiac Involvement
Abstract Number: 2059

Muscle Tension Is Increased in Fibromyalgia
Abstract Number: 2216

Muscle Type I Interferon Gene Expression May Predict Therapeutic Responses to Rituximab in Myositis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].